Treating Early Breast Cancer

The 10-year follow-up data from the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial continue to show that the adjuvant anastrozole significantly reduces the rate of breast cancer recurrence and secondary primary breast cancer in comparison with tamoxifen in postmenopausal, hormone receptor-positive patients, Dr. Aman Buzdar explains.

The 10-year follow-up data from the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial continue to show that the adjuvant anastrozole significantly reduces the rate of breast cancer recurrence and secondary primary breast cancer in comparison with tamoxifen in postmenopausal, hormone receptor-positive patients, Dr. Aman Buzdar explains.

The 10-year follow-up data from the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial continue to show that the adjuvant anastrozole significantly reduces the rate of breast cancer recurrence and secondary primary breast cancer in comparison with tamoxifen in postmenopausal, hormone receptor-positive patients, Dr. Aman Buzdar explains.